Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.05.2026. Verfasst von Xiaozhe Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
Minimal residual disease (MRD) testing is essential for evaluating treatment response among multiple myeloma (MM) patients. Many patients experience MRD progression (MRD‐P) before they meet the criteria for clinical or biochemical progression (PD), thus raising questions about the timing of treatment. In this retrospective study, the effect of early intervention (EI) on prognosis was investigated among 42 newly diagnosed MM patients who developed MRD‐P after initial treatment with autologous stem cell transplantation. In the EI group ( n = 9), treatment was modified at the onset of MRD‐P; in the PD group ( n = 33), treatment was delayed until disease progression occurred. At a median follow‐up of 25 months, compared with the PD group, the EI group demonstrated a longer time to progression (median 34.8 months vs. 6.6 months, p = 0.029), superior overall survival (median not reached vs. 41.0 months, p = 0.034), and significantly higher MRD re‐negativity rates (median 12.6 months vs. 75.9 months, p < 0.001). Multivariate analysis revealed that early intervention was significantly associated with improved MRD re‐negativity (HR = 0.07; p = 0.001). This hypothesis‐generating retrospective study demonstrated that early intervention at MRD‐P onset was associated with improved survival outcomes and higher rates of MRD re‐negativity in this cohort. Despite significant limitations, such as the small sample size, nonrandomized design, and unmeasured confounders, these findings provide preliminary data to inform the design of future prospective randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Förderung
- Guangzhou Municipal Science and Technology Project
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Chen, M., Kuang, L., Liu, J., Huang, B., & Li, J. (2026). Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71911
Vancouver
Li X, Chen M, Kuang L, Liu J, Huang B, Li J. Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71911
BibTeX
@article{Li2026,
author = {Li, Xiaozhe and Chen, Meilan and Kuang, Lifen and Liu, Junru and Huang, Beihui and Li, Juan},
title = {Outcomes Among MM Patients Receiving Early Intervention for MRD Progression Following Autologous Stem Cell Transplantation},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71911}
}
EUVIMED